EQ news

Latest 2 stories · newest Oct 26, 2026

EQ
Equillium Doses First Patient in EQ504 Phase 1 Trial

Equillium's first patient has been dosed in a Phase 1 clinical trial for its AhR modulator, EQ504. In connection with this milestone, the company has approved an additional $20 million in private placement funding.

Offering Oct 26, 2026 sentiment +0.20 SEC filing ↗
EQ
Equillium amends certificate to authorize 410M shares including 400M common stock

Equillium Inc. increased its authorized share capital to 410 million shares (400M common, 10M preferred), each with $0.0001 par value, following stockholder approval. The amendment expands the company's flexibility for future financing, equity compensation, and strategic transactions.

Restructuring May 29, 2026 sentiment +0.10 SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same EQ feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/EQ/newsSTART FREE